Sildenafil Decreases BACE1 and Cathepsin B Levels and Reduces APP Amyloidogenic Processing in the SAMP8 Mouse

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 70, Issue 6, 2015, Pages 675-685

  Orejana, Lourdes ^a   Barros Miñones, Lucía ^a   Jordan, Joaquin ^b   Cedazo Minguez, Angel ^c   Tordera, Rosa M ^a   Aguirre, Norberto ^a   Puerta, Elena ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amyloid ; BACE1; Cathepsin B; SAMP8; Sildenafil

Indexed keywords

ASPARTIC PROTEINASE; BACE PROTEIN, RAT; CALPAIN; CATHEPSIN B; CYCLIN DEPENDENT KINASE 5; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; PURINE DERIVATIVE; SECRETASE; SILDENAFIL; SULFONAMIDE;

AGING; ANIMAL; ANIMAL MODEL; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; HIPPOCAMPUS; METABOLISM; MOUSE; PHOSPHORYLATION;

AGING; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CALPAIN; CATHEPSIN B; COGNITION DISORDERS; CYCLIN-DEPENDENT KINASE 5; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASES; HIPPOCAMPUS; MICE; MODELS, ANIMAL; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; RNA, MESSENGER; SULFONAMIDES;

EID: 84937611090     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glu106     Document Type: Article

References (84)

1. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181-193. doi:10.1016/j.neuron. 2004.09.010
2. Benilova I, Karran E, De Strooper B. The toxic A? oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci. 2012;15:349-357. doi:10.1038/nn.3028
3. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387-390. doi:10.1038/34910
4. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-741.
5. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787-12794. doi:10.1523/JNEUROSCI.3657-09.2009
6. Hook V, Schechter I, Demuth HU, Hook G. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem. 2008;389:993-1006. doi:10.1515/BC.2008.124
7. Cole SL, Vassar R. The basic biology of BACE1: A key therapeutic target for Alzheimer's disease. Curr Genomics. 2007;8:509-530. doi:10.2174/138920207783769512
8. Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: Review. Curr Alzheimer Res. 2012;9:178-183.
9. Hook G, Hook V, Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011;26:387-408. doi:10.3233/JAD-2011-110101
10. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): A novel murine model of accelerated senescence. J Am Geriatr Soc. 1991;39:911-919.
11. Takeda T. Senescence-accelerated mouse (SAM): A biogerontological resource in aging research. Neurobiol Aging. 1999;20:105-110.
12. Canudas AM, Gutierrez-Cuesta J, Rodríguez MI, et al. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech Ageing Dev. 2005;126:1300-1304. doi:10.1016/j. mad.2005.07.008
13. Del Valle J, Duran-Vilaregut J, Manich G, et al. Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis. 2010;19:1303-1315. doi:10.3233/JAD-2010-1321
14. Hosokawa M. A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice. Mech Ageing Dev. 2002;123:1553-1561.
15. Manich G, Mercader C, del Valle J, et al. Characterization of amyloid-? granules in the hippocampus of SAMP8 mice. J Alzheimers Dis. 2011;25:535-546. doi:10.3233/JAD-2011-101713
16. Tomobe K, Nomura Y. Neurochemistry, neuropathology, and heredity in SAMP8: A mouse model of senescence. Neurochem Res. 2009;34:660-669. doi:10.1007/s11064-009-9923-x
17. Ali AK, Banks WA, Kumar VB, et al. Nitric oxide activity and isoenzyme expression in the senescence-accelerated mouse p8 model of Alzheimer's disease: Effects of anti-amyloid antibody and antisense treatments. J Gerontol A Biol Sci Med Sci. 2009;64:1025-1030. doi:10.1093/gerona/glp074
18. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G. From aging to Alzheimer's disease: Unveiling "the switch" with the senescenceaccelerated mouse model (SAMP8). J Alzheimers Dis. 2008;15:615-624.
19. Kumar VB, Farr SA, Flood JF, et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000;21:1769-1775.
20. Morley JE, Farr SA, Flood JF. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem. 2002;78:125-138. doi:10.1006/nlme.2001.4047
21. Morley JE, Kumar VB, Bernardo AE, et al. Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides. 2000;21:1761-1767.
22. Poon HF, Joshi G, Sultana R, et al. Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 2004;1018:86-96. doi:10.1016/j.brainres.2004.05.048
23. Zhou JW, Cheng XR, Cheng JP, Zhou WX, Zhang YX. The activity and mRNA expression of ?-secretase, cathepsin D, and cathepsin B in the brain of senescence-accelerated mouse. J Alzheimers Dis. 2012;28:471-480. doi:10.3233/JAD-2011-111469
24. Orejana L, Barros-Miñones L, Jordán J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescenceaccelerated mouse model. Neurobiol Aging. 2012;33:625.e11-625.e20. doi:10.1016/j.neurobiolaging.2011.03.018
25. Miyamoto M. Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp Gerontol. 1997;32:139-148.
26. Miyamoto M, Kiyota Y, Yamazaki N, et al. Age-related changes in learning and memory in the senescence-accelerated mouse (SAM). Physiol Behav. 1986;38:399-406.
27. Sawano E, Negishi T, Aoki T, Murakami M, Tashiro T. Alterations in local thyroid hormone signaling in the hippocampus of the SAMP8 mouse at younger ages: Association with delayed myelination and behavioral abnormalities. J Neurosci Res. 2013;91:382-392. doi:10.1002/jnr.23161
28. Spangler EL, Patel N, Speer D, et al. Passive avoidance and complex maze learning in the senescence accelerated mouse (SAM): Age and strain comparisons of SAM P8 and R1. J Gerontol A Biol Sci Med Sci. 2002;57:B61-B68.
29. Goñi-Allo B, Puerta E, Ramos M, Lasheras B, Jordán J, Aguirre N. Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin depletions: Role of mitochondrial ATP-sensitive potassium channels, Akt and ERK. J Neurochem. 2008;104:914-925. doi:10.1111/j.1471-4159.2007.05042.x
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. doi:10.1006/meth.2001.1262
31. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737-27744. doi:10.1074/jbc.M110.117960
32. Wen Y, Yu WH, Maloney B, et al. Transcriptional regulation of betasecretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008;57:680-690. doi:10.1016/j.neuron.2008.02.024
33. Kindy MS, Yu J, Zhu H, El-Amouri SS, Hook V, Hook GR. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AbetaPP containing the wild-type betasecretase site sequence. J Alzheimers Dis. 2012;29:827-840. doi:10.3233/JAD-2012-111604
34. Hook V, Hook G, Kindy M. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010;391:861-872. doi:10.1515/BC.2010.110
35. Shi C, Zheng DD, Wu FM, Liu J, Xu J. The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3? pathway mediates bilobalide-induced reduction in amyloid ?-peptide. Neurochem Res. 2012;37:298-306. doi:10.1007/s11064-011-0612-1
36. Yagi H, Katoh S, Akiguchi I, Takeda T. Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res. 1988;474:86-93.
37. Rosenberg RN. The molecular and genetic basis of AD: The end of the beginning: The 2000 Wartenberg lecture. Neurology. 2000;54:2045-2054.
38. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc. 2000;283:1571-1577.
39. Matsumura Y, Kitamura E, Miyoshi K, Yamamoto Y, Furuyama J, Sugihara T. Japanese siblings with missense mutation (717Val-Ile) in amyloid precursor protein of early-onset Alzheimer's disease. Neurology. 1996;46:1721-1723.
40. Younkin SG. The amyloid beta protein precursor mutations linked to familial Alzheimer's disease alter processing in a way that fosters amyloid deposition. Tohoku J Exp Med. 1994;174:217-223.
41. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233-234. doi:10.1038/85064
42. Devi L, Ohno M. 7,8-Dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2012;37:434-444. doi:10.1038/npp.2011.191
43. Fukumoto H, Takahashi H, Tarui N, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:11157-11166. doi:10.1523/JNEUROSCI.2884-10.2010
44. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231-232. doi:10.1038/85059
45. Nixon RA, Saito KI, Grynspan F, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann N Y Acad Sci. 1994;747:77-91.
46. Sureda FX, Gutierrez-Cuesta J, Romeu M, et al. Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp Gerontol. 2006;41:360-367. doi:10.1016/j.exger.2006.01.015
47. Tajes M, Gutierrez-Cuesta J, Folch J, et al. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol. 2008;67:612-623. doi:10.1097/NEN.0b013e3181776293
48. Ahlijanian MK, Barrezueta NX, Williams RD, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA. 2000;97:2910-2915. doi:10.1073/pnas.040577797
49. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615-622. doi:10.1038/45159
50. Patzke H, Maddineni U, Ayala R, et al. Partial rescue of the p35-/-brain phenotype by low expression of a neuronal-specific enolase p25 transgene. J Neurosci. 2003;23:2769-2778.
51. Cruz JC, Kim D, Moy LY, et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536-10541. doi:10.1523/JNEUROSCI. 3133-06.2006
52. Higuchi M, Iwata N, Matsuba Y, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 2012;26:1204-1217. doi:10.1096/fj.11-187740
53. Morales-Corraliza J, Berger JD, Mazzella MJ, et al. Calpastatin modulates APP processing in the brains of ?-amyloid depositing but not wild-type mice. Neurobiol Aging. 2012;33:1125.e9-1125.18. doi:10.1016/j.neurobiolaging. 2011.11.023
54. Medeiros R, Kitazawa M, Chabrier MA, et al. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 2012;181:616-625. doi:10.1016/j. ajpath.2012.04.020
55. Nikkel AL, Martino B, Markosyan S, et al. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology. 2012;63:606-612. doi:10.1016/j.neuropharm. 2012.05.011
56. Serenó L, Coma M, Rodríguez M, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009;35:359-367. doi:10.1016/j.nbd.2009.05.025
57. Su Y, Ryder J, Li B, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry. 2004;43:6899-6908. doi:10.1021/bi035627j
58. Ly PT, Wu Y, Zou H, et al. Inhibition of GSK3?-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013;123:224-235. doi:10.1172/JCI64516
59. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789. doi:10.1038/378785a0
60. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci. 2009;29:8075-8086. doi:10.1523/JNEUROSCI.0864-09.2009
61. Puzzo D, Loreto C, Giunta S, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging. 2014;35:520-531. doi:10.1016/j.neurobiolaging.2013.09.002
62. Zhang J, Guo J, Zhao X, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res. 2013;250:230-237. doi:10.1016/j.bbr.2013.05.017
63. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al. Sildenafil restores cognitive function without affecting ?-amyloid burden in a mouse model of Alzheimer's disease. Br J Pharmacol. 2011;164:2029-2041. doi:10.1111/j.1476-5381.2011.01517.x
64. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006;281:25457-25465. doi:10.1074/jbc.M603469200
65. Bannerman DM, Rawlins JN, McHugh SB, et al. Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev. 2004;28:273-283. doi:10.1016/j.neubiorev.2004.03.004
66. Wang ME, Fraize NP, Yin L, et al. Differential roles of the dorsal and ventral hippocampus in predator odor contextual fear conditioning. Hippocampus. 2013;23:451-466. doi:10.1002/hipo.22105
67. Kheirbek MA, Drew LJ, Burghardt NS, et al. Differential control of learning and anxiety along the dorsoventral axis of the dentate gyrus. Neuron. 2013;77:955-968. doi:10.1016/j.neuron.2012.12.038
68. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology. 2004;63:1155-1162.
69. Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis. 2008;13:359-369.
70. Piermartiri TC, Figueiredo CP, Rial D, et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-?(1-40) administration in mice: Evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol. 2010;226:274-284. doi:10.1016/j.expneurol.2010.08.030
71. Wu Y, Zhang AQ, Yew DT. Age related changes of various markers of astrocytes in senescence-accelerated mice hippocampus. Neurochem Int. 2005;46:565-574. doi:10.1016/j.neuint.2005.01.002
72. Pifarre P, Prado J, Baltrons MA, et al. Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol. 2011;121:499-508. doi:10.1007/s00401-010-0795-6
73. Pifarré P, Prado J, Giralt M, Molinero A, Hidalgo J, Garcia A. Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury. J Neurochem. 2010;112:807-817. doi:10.1111/j.1471-4159.2009.06518.x
74. Puerta E, Hervias I, Barros-Miñones L, et al. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis. 2010;38:237-245. doi:10.1016/j.nbd.2010.01.013
75. Pifarré P, Gutierrez-Mecinas M, Prado J, et al. Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Exp Neurol. 2014;251:58-71. doi:10.1016/j.expneurol. 2013.10.021
76. Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002;33:2675-2680.
77. Zhang RL, Chopp M, Roberts C, et al. Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-aged mouse. PLoS One. 2012;7:e48141. doi:10.1371/journal.pone.0048141
78. Barros-Miñones L, Martín-de-Saavedra D, Perez-Alvarez S, et al. Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate. Biochim Biophys Acta. 2013;1832:705-717. doi:10.1016/j.bbadis.2013.02.002
79. Barros-Miñones L, Orejana L, Goñi-Allo B, et al. Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate. Br J Pharmacol. 2013;168:1820-1834. doi:10.1111/bph.12071
80. Chalimoniuk M, Strosznajder JB. Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Mol Chem Neuropathol. 1998;35:77-95.
81. Domek-?opaci?ska K, Strosznajder JB. Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol. 2005;56:15-34.
82. Domek-?opaci?ska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res. 2008;1216:68-77. doi:10.1016/j.brainres.2008.02.108
83. Domek-?opaci?ska KU, Strosznajder JB. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol. 2010;41:129-137. doi:10.1007/s12035-010-8104-x
84. Puerta E, Hervias I, Goñi-Allo B, Lasheras B, Jordan J, Aguirre N. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J Neurochem. 2009;108:755-766. doi:10.1111/j.1471-4159.2008.05825.x